IBD Science for Patients

When you are diagnosed with Crohn’s disease that is concentrated in one specific part of your digestive tract, deciding on your first major treatment step is a crucial decision. For most people, inflammation occurs in the ileocaecal region, which is the junction where the end of your small intestine (the ileum) joins the start of your large bowel (the caecum).

Traditionally, standard care involves starting advanced biological drugs (such as infliximab or adalimumab) to calm gut inflammation. However, for localised disease that has not responded to standard initial treatments, doctors are increasingly considering an alternative option: performing an early ileocaecal resection (a targeted operation to remove just the small, inflamed segment of bowel).

An international study has brought together global data to compare early keyhole surgery directly against starting biologic therapy. The findings show that taking a “surgery-first” approach significantly lowers the risk of needing future operations and allows nearly half of patients to remain completely drug-free years later.

Behind the Evidence: A Meta-Analysis of 1,644 Patients

To compare these two care strategies, researchers conducted a systematic review and meta-analysis.

In medical science, a systematic review and meta-analysis is a high-level research method that searches global databases to collect every relevant clinical trial on a topic. Researchers combine the statistical data from multiple independent studies to reach a clearer, more reliable conclusion.

The research team searched major medical databases, including PubMed, Scopus, and the Cochrane Central Register, identifying 3 clinical studies (including one randomised controlled trial and two long-term observational cohort studies). In total, the analysis evaluated 1,644 adult patients with localised ileocaecal Crohn’s disease who had never taken biologic drugs before:

• Early Resection Group: 799 patients (48.8 per cent) had a surgery-first operation to remove the inflamed bowel segment.
• Biologics Group: 845 patients started on advanced biologic medicines (primarily anti-TNF drugs like infliximab or adalimumab).

---

The Key Findings: 90 Per Cent Lower Surgical Risk and Drug-Free Recovery

By analysing long-term outcomes across the combined patient groups, the research team discovered remarkable differences between the two treatment paths:

1. Massive Reduction in Repeat Surgeries: Patients who underwent early resection had a 91 per cent lower risk of needing additional bowel surgery during follow-up compared to those who started on biologics first (Risk Ratio 0.09, p = 0.01). In medical statistics, a Risk Ratio (RR) compares the likelihood of an event occurring in one group versus another; an RR of 0.09 proves that future surgical need dropped dramatically in the early operation group.
2. Achieving Drug-Free Remission: At the final clinical follow-up across two major studies, nearly half of the early surgery patients (315 out of 650, or 48 per cent) were completely off all IBD medications without needing any further medical or surgical treatment. In contrast, 100 per cent of patients in the biologics-first group required ongoing, long-term medical drug maintenance or subsequent surgery.
3. Equal Options for Treatment Escalation: There was no statistical difference between the two groups regarding whether patients eventually needed to try the alternative therapy, showing that early surgery does not close the door to using biologics later if ever needed.
4. Evaluating Evidence Certainty: The study authors noted that according to the international GRADE system (a scientific tool used to rate how confident researchers are in clinical data), the current certainty of evidence remains low to very low because only three studies were available. This means that while the results are very encouraging, treatment choices must still be carefully tailored to each individual person.

Why This Matters to You as a Patient

If you have been diagnosed with Crohn’s disease localised to your ileocaecal area, this landmark research offers empowering insights for your healthcare journey:

1. Proof That Surgery Can Be a Positive Choice: This study proves that viewing keyhole surgery as an early, proactive choice rather than a “last resort” can offer long-term health benefits. Knowing that nearly half of early surgery patients remain drug-free years later provides wonderful reassurance.
2. Reducing Long-Term Drug Burden: If you feel hesitant about committing to lifelong biologic infusions or self-injections, discussing an early resection with your medical team gives you a viable path toward living medication-free while your gut remains healthy.
3. Empowerment Through Shared Decision-Making: Choosing between early surgery and biologic therapy is an important personal decision. Understanding that early resection dramatically reduces your chances of needing repeat operations allows you to work alongside your gastroenterologist and colorectal surgeon to select the strategy that best fits your lifestyle and goals.

By evaluating both surgical and medical options early in your diagnosis, you can take a confident, active role in protecting your long-term bowel health.